Gastric carcinoma at Tanta Cancer Center: A comparative retrospective clinico-pathological study of the elderly versus the non-elderly

Zeeneldin, Ahmed A.; Ramadan, Hanan; Gammal, Mosaad M. El; Saber, Mohamed; Elgamal, Dina; Sherisher, Mohamed A.

doi:10.1016/j.jnci.2014.04.002

Cited by 18 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that intestinal-type adenocarcinoma accounts 63.5% of our cases, which is consistent with the reported data by Zeeneldin et al [16], was 47.6%. Most of our cases belong to moderately differentiated tumours (58.9%), which is in contrast to the other study, that they reported 58.1% of cases belong to tumours with G-III /IV [16]. …”

Section: Discussionsupporting

confidence: 93%

Her2/neu Protein Expression and Oncogene Amplification in Gastric Carcinoma with Clinico-Pathological Correlation in Egyptian Patients

Hadi

Hindawi

Hareedy

et al. 2016

Open Access Maced J Med Sci

View full text Add to dashboard Cite

AIM:Amplification of the Her2/neu gene and overexpression of the Her2/neu protein in gastric carcinoma (GC) is a golden criterion for target therapy with trastuzumab (Herceptin). We aim to evaluate the immunohistochemical protein expression and amplification of the oncogene Her2/neu by FISH technique in the epithelial gastric carcinoma and to compare their association with different clinicopathologic parameters aiming at identifying positive cases that may benefit from targeted therapy.MATERIALS AND METHODS:This study was done on eighty-five tumour tissue samples from patients with GC as well as thirty non-malignant lesions (Gastritis, intestinal metaplasia, adenoma with low-grade dysplasia, adenoma with high-grade dysplasia). All were immunohistochemically stained with Her2/neu antibody.RESULTS:All equivocal and some selected GC cases were submitted for FISH technique to detect Her2/neu gene amplification. By immunohistochemistry twenty-three cases (27%) were defined as positive for Her2/neu gene amplification and/or protein overexpression. The levels of Her2/neu positive (3+), Her2/neu equivocal (2+) and Her2/neu negative (1+/0) were measurable in 14.2%, 32.9% and 52.9% of the samples, respectively. FISH showed that Her2/neu gene was amplified in 22 cases, 10 Her2/neu positive (3+), 11 (39.3%) Her2/neu equivocal (2+) and 1 Her2/neu negative (1+) cases with IHC staining those who can benefit from anti Her2/neu target therapy. Her2/neu was overexpressed positivity (3+) more in intestinal type and mixed carcinoma, and moderately differentiated tumours. None of gastritis, intestinal metaplasia or adenoma with low-grade dysplasia cases showed positivity for Her2/neu (3+). The Her2/neu positivity (3+) was associated with both adenocarcinoma cases and high-grade dysplasia (P = 0.002).CONCLUSIONS:The results highlight the necessity of FISH test for further categorization when gastric cancer cases are equivocal (2+) by IHC to determine eligibility for the targeted therapy. Stepwise increase in the expression of Her2/neu was seen in low-grade dysplasia, high-grade dysplasia and carcinoma cases implying its role in cancer evolution. Overexpression of Her 2/neu in GC patients can be promising in selecting those who can get benefit from anti-Her2/neu target therapy.

show abstract

Section: Discussionsupporting

confidence: 93%

Her2/neu Protein Expression and Oncogene Amplification in Gastric Carcinoma with Clinico-Pathological Correlation in Egyptian Patients

Hadi

Hindawi

Hareedy

et al. 2016

Open Access Maced J Med Sci

View full text Add to dashboard Cite

show abstract

“…The PYLL and DALY rates for the elderly in the present study were more than two times those of the young, which was probably related with the large number of deaths in the elderly. Other studies have reported similar results, with >80% of cancer deaths occurring in the elderly [ 29 ]. Cancer-related mortality in the elderly in the present study was 13.53 times that of the young.…”

Section: Discussionsupporting

confidence: 73%

High Cancer Burden in Elderly Chinese, 2005–2011

Zhang

Yan

et al. 2015

IJERPH

View full text Add to dashboard Cite

Objective: Cancer risk increases with age, creating a challenge for the Chinese health system. To inform public health policy and research, we evaluated the cancer burden in elderly Chinese. Methods: Based on the published Chinese Cancer Registry Annual Report or related literature and the China Population and Employment Statistics Yearbooks, we estimated the cancer burden of elderly Chinese, who were representative of the Chinese population. We calculated the cancer incidence, cancer-related mortality, potential years of life lost (PYLL), and disability-adjusted life years (DALYs) in 2005–2011 by age, sex, district (rural, urban), and calendar year using national cancer registry, publication, and census data. The relative ratios (RRs) were determined between the elderly (≥60 years) and young (<60 years). Results: Cancer incidence and related mortality in the elderly were 8.47 and 13.96 times, respectively, those in the young. The PYLL and DALY rates of the elderly were 1.63 and 5.00 times, respectively, those in the young. The PYLL and DALY rates for elderly men and rural districts were higher than for elderly women and urban districts. The RRs for male sex and rural districts were higher than for female sex and urban districts. RRs increased sharply from 2005 to 2011. Conclusions: The cancer burden in elderly Chinese was higher in men and rural districts than in women and urban districts, which creates considerable challenges for the Chinese health care system. Comprehensive measures for cancer prevention and treatment in the elderly are needed.

show abstract

“…According to a recent Egyptian study, the median overall survival, disease-free survival and progression-free survival for GC patients are 6, 17 and 3 months, respectively [16].…”

Section: Discussionmentioning

confidence: 99%

HER-2/Neu Status in Gastric Carcinomas in a Series of Egyptian Patients and Its Relation to Ki-67 Expression

El-Gendi¹,

Talaat²,

Abdel-Hadi³

2015

OJPathology

View full text Add to dashboard Cite

Objective: HER-2/neu status in gastric carcinomas (GCs) has not been studied before in the Egyptian population. Materials and Methods: Seventy-three GCs were evaluated for the expression of HER-2/neu and Ki-67 using immunohistochemistry (IHC). Fluorescence in situ Hybridization (FISH) was done for HER2/neu IHC score 2+ cases. Results: Out of the 73 gastric carcinomas, 23 (31.5%) were score 0, 17 (23.3%) were score 1+, 23 (31.5%) were score 2+, and 10 (13.7%) were score 3+. FISH analysis revealed that the HER-2/neu gene was amplified in 11 out of the 23 cases (47.8%) scored 2+ by IHC. Therefore, the overall HER-2/neu positivity rate was 28.8% and it was significantly associated with higher T-stage and lymphovascular invasion (LVI). The Ki-67 expression rate ranged between 10% and 100%, with 84.9% of the cases (n = 62) featuring high Ki-67 scores. High Ki-67 score was significantly associated with male sex, tumor grade, and number of positive nodes. HER-2/neu protein expression correlated significantly with Ki-67 score. Twenty tumors showed combined HER-2/neu positivity and high Ki-67 score and were significantly associated with higher T-stage and occurrence of LVI, implying a more aggressive behavior. Conclusions: The rate of HER-2/neu positive GCs in our series simulates universal rates, thereby mandating routine evaluation of HER-2/neu status in all GCs submitted to our laboratory to benefit from trastuzumab therapy. Further studies on a larger number of GCs are required to prove that the concurrent HER-2/neu positivity and high Ki-67 score are markers of worse prognosis.

show abstract

Gastric carcinoma at Tanta Cancer Center: A comparative retrospective clinico-pathological study of the elderly versus the non-elderly

Abstract: Compared to the non-elderly, GC in the elderly has similar clinico-pathological characteristics and exhibits comparable outcomes with the same treatment options. Treatments should be tailored to each patient.

Cited by 18 publications

References 31 publications

Her2/neu Protein Expression and Oncogene Amplification in Gastric Carcinoma with Clinico-Pathological Correlation in Egyptian Patients

Her2/neu Protein Expression and Oncogene Amplification in Gastric Carcinoma with Clinico-Pathological Correlation in Egyptian Patients

High Cancer Burden in Elderly Chinese, 2005–2011

HER-2/Neu Status in Gastric Carcinomas in a Series of Egyptian Patients and Its Relation to Ki-67 Expression

Contact Info

Product

Resources

About